Top Page
Paradigm Biopharmaceuticals
(Sydney:PAR)
Paradigm Biopharmaceuticals (PAR) vs. S&P 500 (SPY)
Paradigm Biopharmaceuticals Business Overview & Revenue Model
Paradigm Biopharmaceuticals Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 65.80K | 46.76K | 79.22K | 20.55K | 0.00 | Gross Profit |
| 56.81K | -125.72K | -257.78K | -288.65K | -213.12K | EBIT |
| -65.19M | -59.22M | -47.01M | -42.34M | -16.96M | EBITDA |
| -64.54M | -59.06M | -46.82M | -42.13M | -15.70M | Net Income Common Stockholders |
| -58.65M | -51.91M | -39.25M | -34.30M | -12.30M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 17.87M | 56.38M | 39.72M | 71.08M | 104.67M | Total Assets |
| 27.39M | 67.07M | 50.69M | 84.79M | 112.36M | Total Debt |
| 239.33K | 341.67K | 616.67K | 751.84K | 873.69K | Net Debt |
| -17.58M | -55.99M | -39.06M | -70.28M | -103.05M | Total Liabilities |
| 3.58M | 13.39M | 8.38M | 6.52M | 4.18M | Stockholders Equity |
| 23.81M | 53.68M | 42.31M | 78.27M | 108.18M |
| Cash Flow | Free Cash Flow | |||
| -65.94M | -45.19M | -32.21M | -34.96M | -10.22M | Operating Cash Flow |
| -65.94M | -45.19M | -32.21M | -34.93M | -10.09M | Investing Cash Flow |
| 0.00 | 0.00 | 1.00 | 668.37K | 5.62M | Financing Cash Flow |
| 28.18M | 62.53M | 70.12K | 1.00M | 36.05M |
Paradigm Biopharmaceuticals Technical Analysis
Paradigm Biopharmaceuticals Peers Comparison
Paradigm Biopharmaceuticals Corporate Events
Paradigm Biopharmaceuticals has announced a General Meeting to seek shareholder approval for two key resolutions. The first resolution involves ratifying the issuance of 40 million shares to raise $16 million, which will support the company’s Phase 3 clinical trial for iPPS in osteoarthritis and other operational needs. The second resolution proposes amendments to the company’s constitution, including provisions for virtual shareholder meetings and updates to comply with ASX Listing Rule changes. These measures aim to enhance Paradigm’s financial flexibility and operational efficiency, potentially impacting its market positioning and stakeholder engagement.
Paradigm Biopharmaceuticals has made significant progress in its global phase 3 clinical trial for iPPS, a treatment for knee osteoarthritis. The company secured ethics approval in Australia and appointed Advanced Clinical as the CRO to support the trial’s execution. With a cash balance of $24.56 million, Paradigm is poised to begin patient dosing in Q2 2025. The trial, involving 466 patients, will assess the efficacy of iPPS through various endpoints, including pain scores and imaging studies. Paradigm’s strategic initiatives, including a loyalty program to raise capital and active investor engagement, position the company well for future growth.
Paradigm Biopharmaceuticals Ltd. announced its participation in the NWR Virtual Healthcare Conference, where Chief Medical Officer Dr. Donna Skerrett will present. This engagement underscores Paradigm’s commitment to addressing unmet medical needs and highlights its strategic efforts to enhance visibility and stakeholder engagement in the healthcare sector.
Paradigm Biopharmaceuticals Ltd. reported a significant decrease in losses for the half-year ending December 2024, with a net loss of $5.92 million compared to $44.13 million in the previous period. This improvement is primarily due to reduced research and development costs following the conclusion of the PARA_OA_002 study, which was critical in determining the optimal dosing for their Phase 3 osteoarthritis treatment. Despite the reduced losses, the company anticipates continued financial challenges as it progresses with its clinical and regulatory efforts.
Paradigm Biopharmaceuticals Ltd. announced that it has received ethics approval from Australia’s centralised Human Research Ethics Committee for its pivotal PARA_OA_012 Phase 3 trial, which evaluates the safety and efficacy of iPPS for treating knee osteoarthritis. This approval facilitates a streamlined and efficient trial process across multiple Australian sites, with participant recruitment and dosing expected to begin in the second quarter of 2025. The trial, which aims to enroll 466 participants globally, marks a significant step in Paradigm’s mission to bring transformative therapies to osteoarthritis patients, leveraging Advanced Clinical’s expertise in osteoarthritis research.
Paradigm Biopharmaceuticals Ltd. announced a change in the director’s interest notice, indicating that Matthew James Fry, a director of the company, has acquired 354,958 listed options expiring on February 11, 2026, through a Loyalty Options Offer. This acquisition reflects potential strategic moves by the company to strengthen leadership engagement and align interests with long-term company goals, which could influence stakeholders’ confidence and the company’s positioning in the biopharmaceutical market.
Paradigm Biopharmaceuticals Ltd has announced a change in the director’s interest in securities, specifically regarding options expiring in February 2026. The director, Paul Rennie, has acquired a significant number of options, which reflects a potential strategic positioning or confidence in the company’s future performance. This change may have implications for investor perception and the company’s stock market presence.
Paradigm Biopharmaceuticals Ltd. has issued 97,360,143 new securities, which are options expiring on February 11, 2026, as part of a previously announced transaction. This new issuance indicates Paradigm’s ongoing efforts to enhance its financial position and strategic flexibility in the pharmaceutical sector.